We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-3.57%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.86B
AUM Growth
-$642M
Cap. Flow
-$108M
Cap. Flow %
-2.23%
Top 10 Hldgs %
44.28%
Holding
142
New
24
Increased
23
Reduced
21
Closed
24

Top Buys

Rank Stock Value
1
UPB
Upstream Bio Inc
UPB
+$127M
2
EW icon
Edwards Lifesciences
EW
+$80.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$78.7M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$43.5M
5
CYTK icon
Cytokinetics
CYTK
+$42.4M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$81.3M
2
ELV icon
Elevance Health
ELV
+$55.2M
3
BIIB icon
Biogen
BIIB
+$51.3M
4
MRK icon
Merck
MRK
+$50.1M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$47.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
51
DELISTED
Amicus Therapeutics
FOLD
$21.5M 0.44%
2,285,400
+1,715,100
+301% +$17.8M
SCPH
52
DELISTED
scPharmaceuticals
SCPH
$21.5M 0.44%
6,059,528
– –
RAPT
53
DELISTED
RAPT Therapeutics
RAPT
$20.8M 0.43%
+1,641,908
New +$20.9M
TYRA icon
54
Tyra Biosciences
TYRA
$1.82B
$20.4M 0.42%
1,470,086
+701,448
+91% +$12.7M
MLYS icon
55
Mineralys Therapeutics
MLYS
$2.36B
$19.8M 0.41%
1,611,637
-391,302
-20% -$5.12M
GILD icon
56
CALL
Gilead Sciences
GILD
$166B
$18.5M 0.38%
+200,000
New +$18M
GPCR icon
57
Structure Therapeutics
GPCR
$3.38B
$17.7M 0.36%
652,028
+268,323
+70% +$9.52M
KROS icon
58
Keros Therapeutics
KROS
$197M
$16.1M 0.33%
1,018,734
– –
CCCC icon
59
C4 Therapeutics
CCCC
$389M
$15.8M 0.32%
4,377,900
– –
MEDP icon
60
Medpace
MEDP
$15.9B
$14.9M 0.31%
44,900
– –
VSTM icon
61
Verastem
VSTM
$534M
$14.8M 0.3%
2,862,448
– –
PRLD icon
62
Prelude Therapeutics
PRLD
$367M
$13.9M 0.29%
10,909,256
– –
CRBP icon
63
Corbus Pharmaceuticals
CRBP
$167M
$13.8M 0.28%
1,172,287
+259,735
+28% +$4.36M
FBRX icon
64
Forte Biosciences
FBRX
$1.57B
$13.6M 0.28%
+600,000
New +$7.14M
ITCI
65
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$13.6M 0.28%
+163,000
New +$13.4M
SLRN
66
DELISTED
ACELYRIN
SLRN
$12.6M 0.26%
4,001,711
– –
ABCL icon
67
AbCellera Biologics
ABCL
$1.67B
$12.2M 0.25%
4,180,768
– –
ADCT icon
68
ADC Therapeutics
ADCT
$137M
$11.9M 0.24%
5,968,451
+1,434,650
+32% +$3.75M
ACET icon
69
Adicet Bio
ACET
$76.7M
$11M 0.23%
715,446
– –
PMVP icon
70
PMV Pharmaceuticals
PMVP
$57.6M
$9.78M 0.2%
6,475,291
– –
UHS icon
71
CALL
Universal Health Services
UHS
$10B
$8.97M 0.18%
+50,000
New +$10.2M
NMRA icon
72
Neumora Therapeutics
NMRA
$311M
$8.53M 0.18%
804,996
-695,004
-46% -$8.33M
QTTB icon
73
Q32 Bio
QTTB
$445M
$7.75M 0.16%
2,252,987
– –
GERN icon
74
Geron
GERN
$911M
$7.67M 0.16%
+2,168,000
New +$8.66M
AVTX icon
75
Avalo Therapeutics
AVTX
$1.01B
$7.18M 0.15%
967,000
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2024 Portfolio in Review

As of Q4 2024, OrbiMed held 142 positions worth $4.86B, down 12% from $5.5B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

OrbiMed's Q4 2024 filing shows 24 new, 23 increased, 21 reduced and 24 closed positions. Its largest new stake was Upstream Bio Inc: 5,693,589 shares worth $93.6M. The largest sale was Amgen, an estimated $81.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

  • OrbiMed's largest Q4 2024 buy was Upstream Bio Inc: 5,693,589 shares worth $93.6M.
  • OrbiMed added most to Neurocrine Biosciences in Q4 2024, an estimated $78.7M increase.
  • OrbiMed's biggest Q4 2024 reduction was Biogen, cutting an estimated $51.3M.
  • OrbiMed fully exited Amgen in Q4 2024, selling an estimated $81.3M.
  • OrbiMed's ten largest holdings make up 44% of its $4.86B portfolio in Q4 2024.
  • OrbiMed opened 24 new positions and closed 24 in Q4 2024.
  • OrbiMed's portfolio value fell 12% quarter-over-quarter to $4.86B.

Based on OrbiMed's 13F filing for Q4 2024, filed 14 Feb 2025.